Reuters -- U.S. drug reviewers questioned findings from biotech company Allos Therapeutics Inc on the effectiveness of its proposed drug for an aggressive type of lymphoma, documents released on Friday showed.
Reuters -- U.S. drug reviewers questioned findings from biotech company Allos Therapeutics Inc on the effectiveness of its proposed drug for an aggressive type of lymphoma, documents released on Friday showed.
